$ILMN

Meister Keith A. sold $1.9M of ILMN (indirect holdings)

Meister Keith A. sold 11,760 indirectly-held shares of ILLUMINA, INC. (ILMN) at $159.57 ($1.88M total) on 2026-05-29.

Original reporting
SEC EDGAR · Meister Keith A.
Published Jun 1, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The key tradable element is the disclosed sale size (~$1.88M) and the absence of a pre-arranged 10b5-1 plan, which can modestly influence short-term sentiment.

02

Market read

A director sold shares at ~$159.57; traders may monitor for follow-on insider activity or corroborating fundamental news.

03

What to watch

No 10b5-1 plan is noted, but the filing does not state motive, tax needs, or diversification targets; insider sales often have non-informational drivers.

Relevance 6/10Novelty 6/10Timing: Filed June 1, covering a sale executed May 29

Background

This is an SEC Form 4 insider transaction disclosure for Illumina (director role).

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold 11,760 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and typically fades unless paired with other company news.

Evidence & confidence

The filing provides a specific sale price/value and confirms it was not under a pre-arranged 10b5-1 plan, but it does not include new operational/financial information.

Market effects

Limited read-through to biotech/life-science tools; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio management; without additional context, it may not signal reduced confidence.

Key entities

  • Illumina, Inc.

    Issuer of the securities sold by a director; subject of the insider transaction disclosure.

  • Keith A. Meister

    Director who executed an open-market sale of ILMN shares.

Related articles

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.